Journal article
A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC).
Abstract
CRA7004
Background: Selenium was reported to have possible lung cancer chemopreventive benefits based on a large skin cancer trial secondary observation. (JAMA 1996; 276: 1957-1963). Since that time, research continued to suggest that Se could decrease risk of second primary tumor (SPT) in persons with resected NSCLC. In 2007, a publication from another group suggested an increased association of Se with type 2 diabetes …
Authors
Karp DD; Lee SJ; Shaw Wright GL; Johnson DH; Johnston MR; Goodman GE; Clamon GH; Okawara GS; Marks R; Ruckdeschel JC
Journal
Journal of Clinical Oncology, Vol. 28, No. 18_suppl, pp. cra7004–cra7004
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 20, 2010
DOI
10.1200/jco.2010.28.18_suppl.cra7004
ISSN
0732-183X